Scientists 'put positive spin' on breast cancer studies
Jeremy Laurance is a writer on health issues. He is former health editor of The Independent and the i and has covered the specialism for more than 20 years. He thinks the harm medicine does is under-appreciated, the harm it prevents over-rated, and that cycling works better than most drugs. He was named Specialist Journalist of the Year in the 2011 British Press Awards.
Thursday 10 January 2013
Scientists involved in breast cancer research tend to exaggerate the positives and underplay the negatives of their findings, a new study suggests.
As a result, patients may be given treatments that are less effective than claimed and with worse side-effects than reported.
In two-thirds of the reports studied, the scientists played down the nastiest side-effects of their trials, especially where the treatments also showed significant benefits.
The team, from Princess Margaret Hospital in Toronto, Canada, say they found no influence from sponsors of breast cancer trials, whether in the drug industry or in academic institutions.
But they note that "the pharmaceutical industry is increasingly influential in clinical trial sponsorship". Over the past 30 years, the number of phase 3 trials (final testing) sponsored by the industry has risen from 24 per cent to 72 per cent, they say.
One explanation for the findings is that scientists want to be noticed, they say. Positive results get more attention than negative findings and are more likely to be cited in the scientific literature, which is important for boosting scientific careers.
Professor Ian Tannock, who led the study, said: "Better and more accurate reporting is urgently needed. Journal editors and reviewers, who give their expertise on the topic, are very important in ensuring this happens."
Richard Francis, research manager at the UK charity Breakthrough Breast Cancer, said: "We strongly believe that making clinical trial data freely available would decrease the potential for 'spin' by allowing more researchers to investigate the results.
"This will ensure trials are accurately assessed by regulatory bodies, allow comparisons with other studies and prevent duplication of trials."
- 1 Malaysian cyclist could face disciplinary action after 'Save Gaza' gloves protest
- 2 Is Gideon Levy the most hated man in Israel or just the most heroic?
- 3 Fifty Shades of Grey trailer provokes moral outrage from US parenting groups
- 4 McDonald’s removes chicken nuggets from the menu in Hong Kong amid major food scare
- 5 Students offered grants if they tweet pro-Israeli propaganda
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
Malaysia Airlines MH17 crash: victims’ bodies bundled in black bags and loaded onto trains
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
£600 - £650 per day: Orgtel: Conduct Risk Liaison Manager - Banking - London -...
Highly Attractive Package: Austen Lloyd: CITY - COMMERCIAL LITIGATION - GLOBAL...
£65000 - £75000 per annum + Benefits: Progressive Recruitment: The client is a...
£40000 - £45000 per annum: Ashdown Group: A well-established software house ba...